Evidence map›Paper›PMID 34014035›Full record

ArticleEMBO molecular medicine2021

High-throughput screening identifies suppressors of mitochondrial fragmentation in OPA1 fibroblasts.

Emma Cretin, Priscilla Lopes, Elodie Vimont, Takashi Tatsuta, Thomas Langer, Anastasia Gazi, Martin Sachse, Patrick Yu-Wai-Man, Pascal Reynier, Timothy Wai

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular mechanisms of mitochondrial dynamics.Nature reviews. Molecular cell biology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2023
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Emma CretinMitochondrial Biology Group, Institut Pasteur, CNRS UMR 3691, Paris, France.ORCID 0000-0002-8423-233X
Priscilla LopesMitochondrial Biology Group, Institut Pasteur, CNRS UMR 3691, Paris, France.
Elodie VimontMitochondrial Biology Group, Institut Pasteur, CNRS UMR 3691, Paris, France.
Takashi TatsutaMax-Planck-Institute for Biology of Ageing, Cologne, Germany.ORCID 0000-0003-0003-0587
Thomas LangerMax-Planck-Institute for Biology of Ageing, Cologne, Germany.ORCID 0000-0003-1250-1462
Anastasia GaziUTechS Ultrastructural Bio Imaging, Institut Pasteur, Paris, France.ORCID 0000-0002-2922-3625
Martin SachseUTechS Ultrastructural Bio Imaging, Institut Pasteur, Paris, France.ORCID 0000-0001-5981-9166
Patrick Yu-Wai-ManCambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7847-9320
Pascal ReynierLaboratoire de Biochimie et biologie moléculaire, Centre Hospitalier Universitaire, Angers, France.ORCID 0000-0003-0802-4608
Timothy WaiMitochondrial Biology Group, Institut Pasteur, CNRS UMR 3691, Paris, France.ORCID 0000-0002-6770-6222
Centre National de la Recherche Scientifique · FRInstitut Pasteur · FRMax Planck Institute for Biology of Ageing · DEUniversity of Cambridge · GBUniversity of Cologne · DE

Funding

Department of Health BRC-1215-20014Medical Research Council G0701386Medical Research Council G0800674Medical Research Council G1002570Medical Research Council MR/S005021/1
6 · The paper itself

Abstract

Mutations in OPA1 cause autosomal dominant optic atrophy (DOA) as well as DOA+, a phenotype characterized by more severe neurological deficits. OPA1 deficiency causes mitochondrial fragmentation and also disrupts cristae, respiration, mitochondrial DNA (mtDNA) maintenance, and cell viability. It has not yet been established whether phenotypic severity can be modulated by genetic modifiers of OPA1. We screened the entire known mitochondrial proteome (1,531 genes) to identify genes that control mitochondrial morphology using a first-in-kind imaging pipeline. We identified 145 known and novel candidate genes whose depletion promoted elongation or fragmentation of the mitochondrial network in control fibroblasts and 91 in DOA+ patient fibroblasts that prevented mitochondrial fragmentation, including phosphatidyl glycerophosphate synthase (PGS1). PGS1 depletion reduces CL content in mitochondria and rebalances mitochondrial dynamics in OPA1-deficient fibroblasts by inhibiting mitochondrial fission, which improves defective respiration, but does not rescue mtDNA depletion, cristae dysmorphology, or apoptotic sensitivity. Our data reveal that the multifaceted roles of OPA1 in mitochondria can be functionally uncoupled by modulating mitochondrial lipid metabolism, providing novel insights into the cellular relevance of mitochondrial fragmentation.

Indexed as

High-Throughput Screening AssaysOptic Atrophy, Autosomal DominantDNA, MitochondrialFibroblastsGTP PhosphohydrolasesHumansDNA, MitochondrialGTP PhosphohydrolasesOPA1 protein, humangenetic modifiershigh-throughput screeningmitochondrial dynamicsOPA1phospholipid metabolism

Identifiers

PMID34014035
PMCPMC8185549
OpenAlexW3163049119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.